Vladimir Vinogradov, head of the Laboratory of Solution Chemistry of Advanced Materials and Technologies, ITMO. Source: Press photo
In cooperation with the Mariinsky Hospital in Saint Petersburg, scientists at ITMO University are working to develop a drug that can be targeted at a blood clot by means of a magnetic field. Results of their research have been published in Scientific Reports.
The new drug is safe for intravenous injection and is able to dissolve clots up to 4000 times more efficiently than ordinary enzyme-based drugs.
In thrombosis emergencies, the clot must be eliminated within four hours. If not, then the lack of blood flow can destroy body tissue. Even if the patient is fortunate enough to undergo thrombolysis, there are likely to be numerous complications caused by the thrombolytic drug, which is a specific enzyme injected intravenously to dissolve blood clots.
Russian scientists instead offer a composite material that can deliver thrombolytic enzymes in a safe and targeted manner. The new material is composed of a porous magnetite structure and molecules of urokinase, which is an enzyme frequently used in medicine as a thrombolytic agent.
The composite material is used to create a thrombolytic coating for artificial blood vessels and stable injectable solutions that are made of nano-sized particles. These can be easily localized near the clot through an external magnetic field. Even more crucially, the magnetite structure also protects enzymes from various inhibitors that are present in the blood and which can deactivate thrombolytic medications.
“Usually, in order to achieve a prolonged effect for such drugs, the enzyme is placed inside a polymeric matrix and is then gradually released from the matrix and eventually loses all activity,'' said Andrey Drozdov, lead author of the study and researcher at the Laboratory of Solution Chemistry of Advanced Materials and Technologies (LSCAMT).
“However, we have demonstrated that enzymes protected by using our method do not lose therapeutic properties over extended periods of time and even after repeated use. The rate at which the new drug can dissolve the clot outperforms unprotected enzymes by about 4,000 times,” he said.
This work is a logical continuation of earlier studies devoted to placing enzymes into a sol-gel magnetite matrix, and the production of magnetically controlled bioactive systems.
“The results may soon allow us to try out the new thrombolytic system on mammals, and we are now preparing for preclinical studies,” said Vladimir Vinogradov, head of LSCAMT.
All rights reserved by Rossiyskaya Gazeta.